文献速递免疫规划传染病防控与疫情报告

以色列2021年1月至8月两波疫情期间接种疫苗后突破性COVID-19住院患者的多中心比较队列研究

Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study.
PubMed 文献 · Euro Surveill · 2022-01-01

在以色列开展的多中心观察性队列研究,比较Delta波接种疫苗突破感染住院患者与未接种住院患者及早期Alpha波突破感染住院患者。主要结局为死亡或机械通气。三组结局相似,受年龄和免疫抑制影响而非接种、变异株或接种时间。Delta波接种者突破感染相比未接种者年龄更大、免疫抑制更多,提示疫苗保护;但接种6个月后突破感染发生在更健康患者中,提示免疫力减弱增加脆弱性,作者建议加强针作为对策。

要点

  • Delta波接种突破感染者相比未接种者年龄更大、男性更多、免疫抑制更多
  • 三组死亡或机械通气结局相似,受年龄和免疫抑制影响而非接种、变异株或接种时间
  • 接种6个月后突破感染发生在更健康患者中,提示免疫力减弱增加脆弱性,作者建议加强针

核心结论

  • Delta变异株波期间接种疫苗具有保护作用,表现为接种突破感染者相比未接种住院患者年龄更大且免疫抑制更多。
  • 与早期接种后时期相比,接种6个月后的突破感染发生在更健康的患者中,提示免疫力减弱增加了Delta波期间的脆弱性,作者建议加强针作为对策。

研究设计与样本

  • 以色列多中心观察性队列研究,纳入住院COVID-19患者分为三组:Comirnaty接种后突破感染(VD,2021年6月至8月)、Delta波未接种病例(ND)和早期Alpha波突破感染(VA,2021年1月至4月)。
  • 共纳入343例VD、162例ND和172例VA患者,主要结局为死亡或机械通气。

主要发现

  • VD组相比ND组更可能年龄更大(OR 1.06;95%CI 1.05-1.08)、男性(OR 1.6;95%CI 1.0-2.5)和免疫抑制(OR 2.5;95%CI 1.1-5.5)。
  • 第二剂疫苗至入院中位时间VD组为179天(IQR 166-187),VA组为41天(IQR 28-57.5)。
  • VD组相比VA组更不可能为男性(OR 0.6;95%CI 0.4-0.9)、免疫抑制(OR 0.3;95%CI 0.2-0.5)或患充血性心力衰竭(OR 0.6;95%CI 0.3-0.9)。
  • 三组间结局相似,受年龄和免疫抑制影响,而非接种、变异株或接种时间。

临床怎么用

  • 作者认为免疫力减弱增加了Delta波期间的脆弱性,建议加强针作为对策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundChanging patterns of vaccine breakthrough can clarify vaccine effectiveness.AimTo compare breakthrough infections during a SARS-CoV-2 Delta wave vs unvaccinated inpatients, and an earlier Alpha wave.MethodsIn an observational multicentre cohort study in Israel, hospitalised COVID-19 patients were divided into three cohorts: breakthrough infections in Comirnaty-vaccinated patients (VD; Jun-Aug 2021) and unvaccinated cases during the Delta wave (ND) and breakthrough infections during an earlier Alpha wave (VA; Jan-Apr 2021). Primary outcome was death or ventilation.ResultsWe included 343 VD, 162 ND and 172 VA patients. VD were more likely older (OR: 1.06; 95% CI: 1.05-1.08), men (OR: 1.6; 95% CI: 1.0-2.5) and immunosuppressed (OR: 2.5; 95% CI: 1.1-5.5) vs ND. Median time between second vaccine dose and admission was 179 days (IQR: 166-187) in VD vs 41 days (IQR: 28-57.5) in VA. VD patients were less likely to be men (OR: 0.6; 95% CI: 0.4-0.9), immunosuppressed (OR: 0.3; 95% CI: 0.2-0.5) or have congestive heart failure (OR: 0.6; 95% CI: 0.3-0.9) vs VA. The outcome was similar between all cohorts and affected by age and immunosuppression and not by vaccination, variant or time from vaccination.ConclusionsVaccination was protective during the Delta variant wave, as suggested by older age and greater immunosuppression in vaccinated breakthrough vs unvaccinated inpatients. Nevertheless, compared with an earlier post-vaccination period, breakthrough infections 6 months post-vaccination occurred in healthier patients. Thus, waning immunity increased vulnerability during the Delta wave, which suggests boosters as a countermeasure.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Brosh-Nissimov T, Maor Y, Elbaz M, et al. Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study. Euro Surveill. 2022. PMID: 35593161. doi:10.2807/1560-7917.ES.2022.27.20.2101026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。